Westfield Capital Management CO LP Nektar Therapeutics Transaction History

Westfield Capital Management CO LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 08, 2019	SELL	$16.91 - $36.27 $426,977 - $915,817	-25,250 Closed	0 $0
Q4 2018 Feb 08, 2019	SELL	$30.43 - $56.65 $7.3 Million - $13.6 Million	-240,011 Reduced 90.48%	25,250 $830,000
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $21.2 Million - $31.2 Million	-455,795 Reduced 63.21%	265,261 $16.2 Million
Q2 2018 Aug 13, 2018	SELL	$46.25 - $104.45 $13.5 Million - $30.6 Million	-292,876 Reduced 28.89%	721,056 $35.2 Million
Q1 2018 May 14, 2018	SELL	$57.4 - $108.44 $73.4 Million - $139 Million	-1,279,249 Reduced 55.78%	1,013,932 $108 Million
Q4 2017 Feb 13, 2018	SELL	$23.02 - $60.5 $30.8 Million - $81 Million	-1,339,238 Reduced 36.87%	2,293,181 $137 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $64.6 Million - $87.2 Million	3,632,419	3,632,419 $87.2 Million

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Westfield Capital Management CO LP, based on Form 13F filings with the SEC.

Stay updated on Westfield Capital Management CO LP with notifications on news.